Great 2HFY23 WITH +ve contribution , great outlook getting into 2024 with expected return to +ve EBITDA 50M WITH SAME RESULTS PRIOR TO METRICS SALE AND LESS OPEX indicates the success of the company strategy and women health specialty . Nexstellis OPEX now down to less %25 YOY as the cost is distributed amongest the whole BBP all women health products are marketed by the same sales rep , this is like merging to businesses and operating from the same premises and the same cost and triple the revenue or even more . Higher uptake of Nexstellis YOY , not long until bigger market share in the 8 billion contraceptive us market . Expected sales revenue from nextstllis alone 100 m pre covid
MYX Price at posting:
$3.37 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)